Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 69 Interest Coverage is 0.41 as of Dec. 2025, which is 99% below its 10-year median of 44.44. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.72 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 687 Drug Manufacturers companies, CanSino Biologics ranks worse than 81.95% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. CanSino Biologics's
Operating Income
for the
three
months ended in Dec. 2025 was $0.19 Mil. CanSino Biologics's Interest Expense for the
three
months ended in Dec. 2025 was $-0.46 Mil.
CanSino Biologics's interest coverage for the quarter that ended in Dec. 2025 was 0.41.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for CanSino Biologics's Interest Coverage or its related term are showing as below:
CASBF'
s Interest Coverage Range Over the Past 10 Years
Min: 0.69 Med: 44.44 Max: 88.18
Current: 2.48
CASBF's Interest Coverage is ranked worse than 81.95% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs CASBF: 2.48
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
CanSino Biologics Interest Coverage Related Terms
CanSino Biologics Interest Coverage Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics (CASBF) has a Interest Coverage of 0.41 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on CanSino Biologics and its competitors. This is 99% below median its historical median of 44.44. Over the past decade, CanSino Biologics' Interest Coverage has ranged from 0.69 to 88.18. According to the industry distribution chart, CanSino Biologics ranks #563 out of 687 companies in the Drug Manufacturers industry, placing it in the top 82%.
Is CanSino Biologics' Interest Coverage too high?
CanSino Biologics' current Interest Coverage of 0.41 is 99% below median its 10-year median of 44.44. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 88.18. The Drug Manufacturers industry median Interest Coverage is 12.75. CanSino Biologics' value of 0.41 is 96.8% below this industry median. Based on the distribution chart, CanSino Biologics ranks #563 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #563 out of 687 companies for Interest Coverage. This places CanSino Biologics in the lower half of its industry. The industry median Interest Coverage is 12.75. CanSino Biologics' value of 0.41 is 96.8% below this benchmark. Historically, CanSino Biologics' own Interest Coverage has ranged from 0.69 to 88.18 over the past decade. While the company's 10-year median is 44.44 vs. the industry median of 12.75, CanSino Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current Interest Coverage of 0.41 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current Interest Coverage is 0.41, which is 99% below median its own 10-year median of 44.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.72, compared to a current price of $2.60 — trading 70.2% below its estimated fair value. The current Interest Coverage is 0.41, which is 99% below median its 10-year median of 44.44 and 96.8% below the Drug Manufacturers industry median of 12.75. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Interest Coverage is 0.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $2.60 is trading 70.2% below its estimated GF Value™ of $8.72.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
Interest Coverage: 0.41 (99% below median its 10-year median of 44.44)
GF Value™: $8.72 vs. price of $2.60 (70.2% below fair value)
Industry Position: 96.8% below the Drug Manufacturers median (#563 of 687)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score
Get the complete analysis for CASBF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
